Please try another search
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company’s preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
Name | Age | Since | Title |
---|---|---|---|
Michael Quigley | - | 2021 | Director |
Antoni Ribas | 57 | 2019 | Independent Director & Member of Scientific Advisory Board |
Jeffrey A. Bluestone | 71 | - | Chairman of Scientific Advisory Board |
Kathryn E. Falberg | 63 | 2017 | Independent Director |
David L. Lacey | 72 | 2020 | Independent Director & Member of Scientific Advisory Board |
C. Patrick Machado | 60 | 2019 | Independent Director |
Yasunori Kaneko | 71 | 2015 | Lead Independent Director |
Merdad V. Parsey | 60 | 2020 | Director |
Stefani Spranger | - | 2020 | Member of Scientific Advisory Board |
Andrew J. Perlman | 76 | 2020 | Independent Director |
Nicole Lambert | 50 | 2021 | Independent Director |
Johanna Mercier | 53 | 2024 | Director |
Linda Slanec Higgins | 62 | 2021 | Member of Scientific Advisory Board & Director |
K. Christopher Garcia | - | - | Co-Founder & Member of Scientific Advisory Board |
Terry J. Rosen | 64 | 2015 | Co-Founder, Chairman & CEO |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review